Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Ariadna Giró"'
Publikováno v:
Health Science Reports, Vol 7, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction High‐dose methotrexate (HDMTX) is administered for the treatment of some malignancies. Serious complications after the administration of HDMTX are rare, but occasionally MTX may precipitate in the renal tubes causing a delayed
Externí odkaz:
https://doaj.org/article/99668ef69e5a489f89ef00ceff0c4edd
Autor:
Neus Gimenez, Rupal Tripathi, Ariadna Giró, Laia Rosich, Mònica López-Guerra, Irene López-Oreja, Heribert Playa-Albinyana, Fabian Arenas, José Manuel Mas, Patricia Pérez-Galán, Julio Delgado, Elias Campo, Judith Farrés, Dolors Colomer
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Abstract Chronic lymphocytic leukemia (CLL) is a B lymphoid malignancy highly dependent on the microenvironment. Despite new targeted therapies such as ibrutinib and venetoclax, disease progression and relapse remain an issue. CLL cell interactions w
Externí odkaz:
https://doaj.org/article/eaa533646552409fbba838dfbdc5b89d
Autor:
Elisabeth Silkenstedt, Fabian Arenas, Berta Colom-Sanmartí, Sílvia Xargay-Torrent, Morihiro Higashi, Ariadna Giró, Vanina Rodriguez, Patricia Fuentes, Walter E. Aulitzky, Heiko van der Kuip, Sílvia Beà, Maria L. Toribio, Elias Campo, Mònica López-Guerra, Dolors Colomer
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-15 (2019)
Abstract Background NOTCH1 gene mutations in mantle cell lymphoma (MCL) have been described in about 5–10% of cases and are associated with significantly shorter survival rates. The present study aimed to investigate the biological impact of this m
Externí odkaz:
https://doaj.org/article/c4021314106c4f4abaaa90f1fc1bd397
Autor:
Ariadna Giró-Perafita, Marc Rabionet, Marta Planas, Lidia Feliu, Joaquim Ciurana, Santiago Ruiz-Martínez, Teresa Puig
Publikováno v:
Molecules, Vol 24, Iss 6, p 1027 (2019)
Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance. Furthermore, the enrichment of Breast Cancer Stem Cell (BCSC) features has been found in breast
Externí odkaz:
https://doaj.org/article/74db35d7b2b1400c868f90f2565fde89
Autor:
Adriana Blancafort, Ariadna Giró-Perafita, Glòria Oliveras, Sònia Palomeras, Carlos Turrado, Òscar Campuzano, Dolors Carrión-Salip, Anna Massaguer, Ramon Brugada, Marta Palafox, Jorge Gómez-Miragaya, Eva González-Suárez, Teresa Puig
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0131241 (2015)
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical H
Externí odkaz:
https://doaj.org/article/d0946f7276224e738d25e57de6ec46aa
Autor:
Ricard Ferrer, Alex Soriano, Rafael Cantón, José Luis Del Pozo, Carolina García-Vidal, José Garnacho-Montero, Nieves Larrosa, Pedro Rascado, Miguel Salavert, Vicente Pintado, Ariadna Giró-Perafita, Xavier Badia
Publikováno v:
Scientia
Multi-drug resistance; Risk factor; Colonization Resistencia a múltiples fármacos; Factor de riesgo; Colonización Resistència a múltiples fàrmacs; Factor de risc; Colonització Objective. Risk factors (RFs) associated with infection progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7803a48e56ae5619affc89ace4650ba7
https://doi.org/10.37201/req/062.2022
https://doi.org/10.37201/req/062.2022
Publikováno v:
In Procedia CIRP 2016 49:61-66
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of doxorubicin (50 - 350 nM) for 48h. Experiments were performed three times in triplicate. Results shown are mean {plus minus} SEM. *(p < 0.05), **(p < 0.01)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a0dc4a12d2701027c6a56bd1d40df5d
https://doi.org/10.1158/1078-0432.22462608
https://doi.org/10.1158/1078-0432.22462608
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
cells (A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of cetuximab (0,5 - 4 µM), C75 (20 - 60 µM) or EGCG ( 25 - 150 µM) for 4 days. Results are expressed as mean {plus minus} SEM. Experiments were perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d1b348f65d50d103597c45b45fc82a0
https://doi.org/10.1158/1078-0432.22462596
https://doi.org/10.1158/1078-0432.22462596
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with doxorubicin (50-100-150nM) and C75 (20µM for HCC, HCCDXR; 40µM for 231, 231DXR) or the combination for 48h. (C) 231 and 231DXR and (D) HCC and HCCDXR cells were treated with doxorubi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::443258cd2e2ece25708066dba734bd8f
https://doi.org/10.1158/1078-0432.22462599
https://doi.org/10.1158/1078-0432.22462599